Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
- PMID: 2529544
- PMCID: PMC298116
- DOI: 10.1073/pnas.86.19.7611
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
Abstract
Interleukin 1, an immune response-generated cytokine that stimulates astrocyte proliferation and reactivity (astrogliosis), was present in up to 30 times as many glial cells in tissue sections of brain from patients with Down syndrome and Alzheimer disease compared with age-matched control subjects. Most interleukin 1-immunoreactive glia in Down syndrome and Alzheimer disease were classified as microglia. The number of interleukin 1 immunoreactive neurons did not appear to differ in Down syndrome and Alzheimer disease compared with control brain. Numerous temporal lobe astrocytes in Alzheimer disease and postnatal Down syndrome were intensely interleukin 1-, S-100-, and glial fibrillary acidic protein-immunoreactive and had reactive structure. Interleukin 1 levels in Alzheimer disease temporal lobe homogenates were elevated, as were the levels of S-100 and glial fibrillary acidic protein, two proteins reportedly elevated in reactive astrocytes. These data suggest that increased expression of S-100 in Down syndrome, resulting from duplication of the gene on chromosome 21 that encodes the beta subunit of S-100, may be augmented by elevation of interleukin 1. As a corollary, the astrogliosis in Alzheimer disease may be promoted by elevation of interleukin 1.
Similar articles
-
Developmental changes of S-100 protein and glial fibrillary acidic protein in the brain in Down syndrome.Exp Neurol. 1993 Apr;120(2):170-6. doi: 10.1006/exnr.1993.1052. Exp Neurol. 1993. PMID: 8491278
-
Neuronal plasticity and astrocytic reaction in Down syndrome and Alzheimer disease.J Neurol Sci. 1990 Aug;98(1):63-79. doi: 10.1016/0022-510x(90)90182-m. J Neurol Sci. 1990. PMID: 1977892
-
S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques.J Neurosci Res. 1994 Nov 1;39(4):398-404. doi: 10.1002/jnr.490390406. J Neurosci Res. 1994. PMID: 7884819
-
Growth and development of the brain in Down syndrome.Prog Clin Biol Res. 1991;373:133-52. Prog Clin Biol Res. 1991. PMID: 1838182 Review.
-
Trisomy 21 and the brain.J Neuropathol Exp Neurol. 2004 Jul;63(7):679-85. doi: 10.1093/jnen/63.7.679. J Neuropathol Exp Neurol. 2004. PMID: 15290893 Free PMC article. Review.
Cited by
-
The role of IL-1 family of cytokines in the pathogenesis and therapy of Alzheimer's disease.Inflammopharmacology. 2024 Oct;32(5):2681-2694. doi: 10.1007/s10787-024-01534-8. Epub 2024 Aug 10. Inflammopharmacology. 2024. PMID: 39126573 Review.
-
Dissecting the contribution of human chromosome 21 syntenic regions to recognition memory processes in adult and aged mouse models of Down syndrome.Front Behav Neurosci. 2024 Jul 10;18:1428146. doi: 10.3389/fnbeh.2024.1428146. eCollection 2024. Front Behav Neurosci. 2024. PMID: 39050700 Free PMC article.
-
Pro-resolving lipid mediator reduces amyloid-β42-induced gene expression in human monocyte-derived microglia.Neural Regen Res. 2025 Mar 1;20(3):873-886. doi: 10.4103/NRR.NRR-D-23-01688. Epub 2024 May 17. Neural Regen Res. 2025. PMID: 38886959 Free PMC article.
-
Altered Brain Cholesterol Machinery in a Down Syndrome Mouse Model: A Possible Common Feature with Alzheimer's Disease.Antioxidants (Basel). 2024 Apr 3;13(4):435. doi: 10.3390/antiox13040435. Antioxidants (Basel). 2024. PMID: 38671883 Free PMC article.
-
Alzheimer's-specific brain amyloid interactome: Neural-network analysis of intra-aggregate crosslinking identifies novel drug targets.iScience. 2023 Dec 18;27(1):108745. doi: 10.1016/j.isci.2023.108745. eCollection 2024 Jan 19. iScience. 2023. PMID: 38274404 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials